These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25256668)

  • 1. What is a new drug worth? An innovative model for performance-based pricing.
    Dranitsaris G; Dorward K; Owens RC; Schipper H
    Eur J Cancer Care (Engl); 2015 May; 24(3):313-20. PubMed ID: 25256668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.
    Sachs R; Bagley N; Lakdawalla DN
    J Health Polit Policy Law; 2018 Feb; 43(1):5-18. PubMed ID: 28972020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use.
    Robinson JC; Howell S
    Health Aff (Millwood); 2014 Oct; 33(10):1745-50. PubMed ID: 25288418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach.
    Fuller RL; Goldfield N
    J Ambul Care Manage; 2016; 39(2):143-9. PubMed ID: 26945298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
    Kwon HY; Kim J
    Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Price Models for Multi-indication Drugs: A Systematic Review.
    Campillo-Artero C; Puig-Junoy J; Segú-Tolsa JL; Trapero-Bertran M
    Appl Health Econ Health Policy; 2020 Feb; 18(1):47-56. PubMed ID: 31523756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Information system technologies' role in augmenting dermatologists' knowledge of prescription medication costs.
    DeMarco SS; Paul R; Kilpatrick RJ
    Int J Med Inform; 2015 Dec; 84(12):1076-84. PubMed ID: 26228652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. California's Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing.
    Gudiksen KL; Brown TT; Whaley CM; King JS
    Health Aff (Millwood); 2018 Sep; 37(9):1503-1508. PubMed ID: 30179546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The End of the International Reference Pricing System?
    Persson U; Jönsson B
    Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2.
    Burns TM; Crowell JL; Smith AG
    Muscle Nerve; 2020 Nov; 62(5):573-578. PubMed ID: 32725709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.
    Messori A
    Clin Drug Investig; 2016 Aug; 36(8):599-603. PubMed ID: 27216427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.